Experimental HIV Vaccine Well-Tolerated, Prompts Immune Response In Early Clinical Trials, Researchers Report At IAS 2017
Quartz: There’s a promising new HIV vaccine that can protect against multiple strains at once
“…[R]esearchers from NIAID and Janssen Pharmaceutical Companies, which is owned by Johnson & Johnson, reported results from a successful preliminary clinical trial at the International AIDS Society Conference on HIV Science in Paris. The study, which was called APPROACH, uses a new kind of vaccine that targets several strains of HIV simultaneously, and appears to not cause any lasting side effects in people who receive it…” (Foley, 7/24).
Vox: There’s a promising new HIV vaccine candidate in the pipeline
“…The mosaic vaccine was developed using a computer algorithm to analyze HIV data from around the world and select a range of HIV sequences to include in a shot. It’s called a ‘mosaic’ because it involves taking pieces of different viruses and sticking them together to generate immune responses that can cover a broad range of HIV subtypes. … A word of caution, though: We’re only in the early phase of human testing, and the vaccine could ultimately fail to prevent the virus from spreading among people…” (Belluz, 7/24).
The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.